GPC3 Fc Chimera Protein, Human

1μg (R: reducing condition, N: non-reducing condition).

2e5 of transient transfected anti-GPC3 ScFv CAR-293 cells were stained with 0.01ug  GPC3 Fc Chimera Protein, Human, (Cat. No. UA010680)  and unlable respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor 647 signal was used to evaluate the binding activity. 2e5 of transient transfected anti- GPC3 ScFv CAR-293 cells were stained with isotype and Whitlow/218 Linker-Alexa Fluor® 488 (Fig. D and E). Alexa Fluor® 488 signal was used to evaluate the binding activity.

Immobilized GPC3 Fc Chimera, Human (Cat. No. UA010680) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human GPC3 (Codrituzumab)  with EC50 of 4.39-6.54ng/mL.

Immobilized FGF-basic(146aa) Protein, Human (Cat. No. UA040145) at 2.0μg/mL (100μL/well) can bind GPC3 Fc Chimera Protein, Human (Cat. No. UA010680) with EC50 of 4.99-7.73 ng/ mL.

Immobilized FGF-basic(154aa) Protein, Human (Cat. No. UA040007) at 2.0μg/mL (100μL/well) can bind GPC3 Fc Chimera Protein, Human (Cat. No. UA010680) with EC50 of 3.97-7.23ng/mL.